Dermalogica has achieved a major milestone: the PRO Pen Microneedling System is now officially FDA-cleared as a Class II medical device—a rare distinction in the skincare world. This means only licensed physicians and professional skincare therapists can use the device.
What sets FDA clearance apart? Unlike typical marketing claims, this process demands rigorous standards for efficacy, safety, and reliability. The PRO Pen passed exhaustive clinical and laboratory tests, validating its precision, sterilization protocols, and patient safety. According to Aurelian Lis, Dermalogica’s CEO, this milestone moves the brand into a new league—where treatments are trusted not for hype, but for proven outcomes.
For decades, Dermalogica has led the way in education-driven skincare innovation. The PRO Pen embodies this legacy and offers advanced microneedling technology. The device launches in the US next year, with further details coming soon for practitioners.
This FDA clearance also sparks an industry-wide conversation: As consumer devices saturate the wellness market, will tools like the PRO Pen reinforce the distinct role of trained experts, or further blur the lines between at-home and professional results?
Dermalogica believes the future of skin health will be defined by science, skill, and measurable change—not trends or shortcuts.
Photo credits: Dermalogica Pro Pen
